CTRI/2010/091/000551Other3 期
A Multi-Center, Double-Blind, Double-Mask, Placebo-Controlled, Three-Arm, Parallel-Group, Randomized Study to Evaluate the Therapeutic Equivalence, Efficacy and Safety of a Generic Formulation of Mesalamine Delayed-Release Tablets (800 mg) and Asacol® HD (mesalamine) Delayed-Release Tablets (800 mg) for the Treatment of Patients with Moderately Active Ulcerative Colitis
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients aged 18 or older.
- •2. Patients with established diagnosis of active ulcerative colitis who have recent relapse within 12 weeks before screening. Newly diagnosed patients with sigmoidoscopy and biopsy report suggestive of active ulcerative colitis within 1 year before screening.
- •3. Positive Mucosal friability based on the Contact Friability Test conducted at verge. 4. Colonic involvement with ulcerative colitis more than 15 cm from the anal verge.
- •5. Female or male patients who are surgically sterilized or who are prepared to and agree to practice a barrier form of birth control from screening through 30 days (Females) and 90 days (Males), respectively, from the last dose of study medication. Females who are more than 12 months post-menopausal are also eligible to participate in the study.
- •6. Able to give written informed consent and to comply with the protocol requirements.
- •7. Patients who are literate and able and willing to complete a paper diary to enter scores during the 14-to 21 days period immediately before randomization and the entire 6-week treatment period.
排除标准
- •1. Pregnant or nursing females.
- •2. Patients who have used oral 5-Amino salicylic acid.
- •3. Patients whom the investigator deems likely to require immunosuppressant therapy.
- •4. Administration of immunosuppressive agents within the last 6 weeks before randomization.
- •5. Patients who have used oral corticosteroids within 4 weeks before randomization.
- •6. Patients taking prescription or over the counter anti-diarrheal agents within 7 days before randomization
- •7. Use of Antibiotics, other than topical dermatological antibiotics, within 14 days before randomization
- •8. Patients who receive an experimental drug or procedure within 30days of randomization, or who are likely to receive an experimental drug or procedure during the study through the 30-day period after the final administration of the study medication.
- •9. Patients with clinically active extra intestinal manifestations.
- •10. Patients who have had major gastrointestinal surgery except appendectomy and cholecystectomy.
- •11. Patients with Crohnâ??s disease, isolated proctitis, an intra-abdominal abscess, or a toxic megacolon.
- •12. Patients who have a history of active malignancies within 5 years.
- •13. Patients with clinically significant hepatic, renal, neurological, endocrine or other significant disease that may interfere with the assessment of the study endpoints
- •14. Patients with infectious ulcerative colitis.
- •15. Active drug and/or drug abuse
- •16. Known case of HIV infection or testing positive for HIV antibody.
- •17. Patients with Hepatitis A, B, C, or E infection.
- •18. Patients with serum creatinine of more than 1.5 times of upper limit of normal or liver enzymes of more than 2 times upper limit of normal at screening.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the Safety and Efficacy of Pro-ocular™ topical gel in two different concentration, 0.5% and 1%, when administered in the forehead twice a day for 12 weeks in Patients diagnosed with Dry Eye Syndrome.Dry Eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, in which tear film instability, hyperosmolarity, ocular surface inflammation and damage, neurosensory abnormalities play an etiological role. Patient-reported symptoms for DE include dryness, grittiness, itching, redness, fluctuating visual disturbances and ocular fatigue.MedDRA version: 21.1Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 100000004853EUCTR2019-000747-27-ITSOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA105
进行中（未招募）
不适用
A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006545-13-DEux Biosciences GmbH100
进行中（未招募）
1 期
A Double-Masked, Placebo-Controlled, Multi-Centre, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.Subjects with clinically quiescent sight threatening, non-infectious, intermediate-, anterior and intermediate-, posterior- or pan-uveitis.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006544-66-FRux Biosciences GmbH350
进行中（未招募）
1 期
A Double-Masked, Placebo-Controlled, Multi-Centre, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.EUCTR2006-006544-66-GBux Biosciences GmbH350
进行中（未招募）
不适用
A Double-Masked, Placebo-Controlled, Multi-Centre, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis.Subjects with clinically quiescent sight threatening, non-infectious, intermediate-, anterior and intermediate-, posterior- or pan-uveitis.MedDRA version: 8.1Level: LLTClassification code 10046851Term: UveitisEUCTR2006-006544-66-ATux Biosciences GmbH350